FarmaKology Newsletter - Issue #30
Neurent Medical is a medical device company based in Ireland’s MedTech cluster in Galway. Neurent Medical is developing a minimally invasive treatment for Rhinitis, a condition affecting millions of people worldwide, was founded by Brian Shields and David Townley and originated from the BioInnovate Ireland programme at the National University of Ireland.
EU Commission requests Opinions on safety of resorcinol and propylparaben
The European Commission’s DG Grow has requested separate Opinions from its Scientific Committee on Consumer Safety (SCCS) on the safety of hair dye resorcinol and cosmetics preservative propylparaben.The requests aim to establish the maximum concentrations considered safe for specific uses of the substances in light of the data provided and concerns related their potential endocrine disrupting properties.
ImmuPharma expects second phase III lupus trial to get underway as soon as possible this year
ImmuPharma PLC has hailed the “positive and proactive” progress made by it and partner Avion Pharmaceuticals that will see a second phase III trial of the latter’s drug for lupus get underway “as soon as possible” this year.The pair will meet America’s Food & Drug Administration sometime this quarter to seek guidance for an optimised study of Lupuzor.
China Begins Testing an Antiviral Drug in Coronavirus Patients
China is forging ahead in the search for treatments for people sickened by the new coronavirus that has infected more than 28,000 people in a countrywide epidemic, killed more than 500 and seeded smaller outbreaks in 24 other nations.Patients in a clinical trial will receive a placebo or remdesivir, which has shown promise in laboratory studies.
Startup uses A.I. to identify molecules that could fight coronavirus
Insilico Medicine, a startup based in Rockville, Md., says it has used artificial intelligence to rapidly identify molecules that could form the basis of an effective treatment against the coronavirus at the heart of the current outbreak.
Research & Study
Metastatic Migration in Cancer may be Influenced by Metabolism
Cancer vaccine could boost the effectiveness of immunotherapy
Bezlotoxumab Treatment Reduced C diff Recurrence in Cancer Patients
Addressing the Replication and Reproducibility Crisis in R&D Organizations
When: Feb 11, 2020 02:00 PM Eastern Time (US and Canada)
Register in advance for this webinar:
After registering, you will receive a confirmation email containing information about joining the webinar.
We will address this head-on in our first High Impact Webinar. We will discuss data and processes as an asset. And yes, I said processes! The world is missing the boat on the value of captured, versioned and reproducible processes with regards to data quality, data integrity, and the REPLICATION CRISIS today in Science! We know the pain in Tech Transfer. We have uncovered statistics that range from 11-50% of scientific research reported in journals that can be replicated.
A negative outcome of this is the lack of Model Quality Data (MQD). Without MQD many of the Predictive and Suggestive Science approaches will fall short. This is costing the world not only billions of dollars every year but missed opportunities, discoveries and ultimately the quality of life for millions of beings. https://en.wikipedia.org/wiki/Replication_crisis You are invited to a Zoom webinar.